Oxford BioDynamics partners EpiSwitch platform

Oxford BioDynamics plc (LSE:OBD) said it partnered with an undisclosed major U.S. pharma to use its EpiSwitch epigenetic biomarker platform to develop predictive biomarkers for immuno-oncology therap...